l General Information |
Product Name | CUDC-101 |
General description | CUDC-101 is a potent multi-targeted inhibitor against HDAC, EGFR and HER2, and inhibits class I/II HDACs, but not class III, Sir-type HDACs. |
Synonym | 7-[4-(3-ethynylanilino)-7-methoxyquinazolin-6-yl]oxy-N-hydroxyheptanamide |
Purity | ≥98.0%(HPLC) | CAS Number | 1012054-59-9 |
Formula | C24H26N4O4 | Molecular Weight | 434.49 |
Suitability | BioReagent, suitable for cell culture, etc. |
l Physical and Chemical Information |
Appearance | solid |
Solubility(25℃) | DMSO | ≥15mg/mL |
Ethanol | Insoluble |
Water | Insoluble |
l Biological Information |
Biochem/Physiol
Actions | CUDC-101 is a potent multi-targeted inhibitor against HDAC, EGFR and HER2 with IC50 of 4.4 nM, 2.4 nM, and 15.7 nM, and inhibits class I/II HDACs, but not class III, Sir-type HDACs. |
Application | CUDC-101 has been used in trials studying the treatment of Cancer, Tumors, Liver Cancer, Breast Cancer, and Gastric Cancer, among others. |
l Storage |
Storage temp. | -20℃ |
l Precautions and Disclaimer |
This
product is for R&D use only, not for drug, household, or other uses. |
l References |
1. http://www.drugbank.ca 2. https://ncit.nci.nih.gov 3. https://www.ncbi.nlm.nih.gov |
